Should you buy Neil Woodford’s top 3 holdings Imperial Brands plc, AstraZeneca plc & GlaxoSmithKline plc?

Edward Sheldon looks at the top three holdings of one of the UK’s best known fund managers, Neil Woodford: Imperial Brands plc (LON: IMB), AstraZeneca plc (LON: AZN) and GlaxoSmithKline plc (LON: GSK).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Neil Woodford is among the most well-known fund managers in the UK. Given his star status, many private investors monitor Woodford’s key holdings in an attempt to clone his investment strategy.

So let’s look at the top three holdings in the Woodford Equity Income Fund and examine if they’re worth buying.

Financial market volatility

But first, let’s remember that there could be a great deal of near-term volatility in the financial markets after Friday’s EU referendum Brexit vote. The unexpected result has caused unprecedented amounts of uncertainty and if there’s one thing financial markets don’t like, it’s uncertainty.

Having said that, Woodford has made his stance clear on the result and has said he believes Britain’s long-term economic future will be largely unaffected by the decision to leave the EU. He’s also stated that his portfolio strategy will not change.

So with that in mind, here are Neil Woodford’s largest holdings.

Tobacco King

Woodford’s largest holding (7.6% of the fund) is tobacco giant Imperial Brands (LSE: IMB).

Tobacco stocks don’t suit everyone’s investing tastes, but Woodford has made it clear that he remains a strong fan of both Imperial Brands and rival British American Tobacco.

There’s no doubt Imperial Brands has performed well for his portfolio. The stock has delivered total annualised returns of almost 18% per annum over the last five years. But is this a reason to buy Woodford’s largest holding?

For me, the key question with Imperial Brands comes down to the long-term sustainability of tobacco revenues. I generally look for long-term revenue drivers when searching for investment opportunities, and personally I’m not 100% convinced about the sustainability of the tobacco industry over time.

Having said that, I can see plenty of reasons why investors could be interested in buying Imperial Brands right now though. The stock trades on a respectable P/E ratio of 15.5 times next year’s earnings, yields an excellent dividend of just under 4%, has high levels of free cash flow and could be seen as a ‘defensive’ stock in times of uncertainty.

Another key benefit of Imperial Brands is that it generates revenues from all over the world, so a weaker pound would be good for earnings. If you’re interested in a safety stock for the current volatile environment, Imperial Brands could be worth a look.

Healthcare theme

Woodford’s next two largest holdings are healthcare giants AstraZeneca (LSE: AZN) and GlaxoSmithKline (LSE: GSK) at 7.2% and 6.4% of the portfolio, respectively.

Healthcare is a theme that I like and with the global population ageing, I believe it’s a theme that could drive long-term revenues going forward. It’s also one that could provide some insulation from Brexit-related market volatility as healthcare is also considered to be a defensive sector.

While both companies have struggled for revenue growth over the last few years, a key attraction of these stocks is their sizeable dividend payouts. AstraZeneca yields around 5.1% while GlaxoSmithKline pays out an even bigger 5.4%.

One concern is that last year both companies’ dividends exceeded their earnings from continuing operations, which isn’t ideal. It’s an issue to keep an eye on going forward in the current volatile market. However, I can see the attraction of buckling down with these two healthcare powerhouses.

Edward Sheldon owns shares in GlaxoSmithKline. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

GSK scientist holding lab syringe
Investing Articles

Why is everyone buying GSK shares?

GSK shares have been outperforming the FTSE 100 in 2026. Paul Summers takes a closer look and asks whether this…

Read more »

Middle-aged white man pulling an aggrieved face while looking at a screen
Investing Articles

£10,000 invested in easyJet shares at the start of 2026 is now worth…

Anyone buying easyJet shares will have endured a rough ride since January. Paul Summers wonders whether things could get even…

Read more »

Close-up of a woman holding modern polymer ten, twenty and fifty pound notes.
Investing Articles

5 years ago, £5,000 bought 2,645 Barclays shares. But how many would it buy now?

Despite delivering an impressive return since April 2021, Barclays' shares have lagged the FTSE 100's other banks. James Beard considers…

Read more »

Side of boat fuelled by gas to liquids, advertising Shell GTL Fuel
Investing Articles

5 years ago, £5,000 bought 354 Shell shares. But how many would it buy now?

When it comes to Shell’s numbers, most of them are impressive. And it’s no different when looking at the recent…

Read more »

A rear view of a female in a bright yellow coat walking along the historic street known as The Shambles in York, UK which is a popular tourist destination in this Yorkshire city.
Investing Articles

I asked ChatGPT if I should buy Aviva, Diageo or BAE Systems stock and it said…

Aviva, Diageo and BAE Systems shares are popular FTSE 100 picks. But which of the three does ChatGPT like the…

Read more »

Tesla car at super charger station
Investing Articles

SpaceX’s IPO threatens to leave the Tesla share price on the forecourt

As Elon Musk starts fuelling the engines for a SpaceX IPO, could the Tesla share price get left in the…

Read more »

Investor looking at stock graph on a tablet with their finger hovering over the Buy button
US Stock

A once-in-a-decade chance to buy software stocks?

Michael Burry thinks now is the time to think about buying falling tech stocks. But it might depend on which…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Here’s how a £20k ISA could generate a £1,000 weekly second income

Drip-feeding money into a Stocks and Shares ISA can put you on track to a four-figure second income. Royston Wild…

Read more »